CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 5.9% in March

CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 3,320,000 shares, a drop of 5.9% from the March 15th total of 3,530,000 shares. Based on an average daily trading volume, of 864,800 shares, the short-interest ratio is currently 3.8 days.

Insider Activity at CytomX Therapeutics

In related news, CEO Sean A. Mccarthy sold 20,223 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total transaction of $42,266.07. Following the completion of the transaction, the chief executive officer now owns 524,481 shares of the company’s stock, valued at approximately $1,096,165.29. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 35,024 shares of company stock valued at $73,200 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of CytomX Therapeutics

Several large investors have recently modified their holdings of CTMX. Millennium Management LLC grew its holdings in shares of CytomX Therapeutics by 223.0% in the fourth quarter. Millennium Management LLC now owns 1,719,811 shares of the biotechnology company’s stock worth $2,752,000 after acquiring an additional 1,187,298 shares during the period. Renaissance Technologies LLC lifted its position in CytomX Therapeutics by 62.3% during the second quarter. Renaissance Technologies LLC now owns 1,454,261 shares of the biotechnology company’s stock valued at $2,661,000 after purchasing an additional 558,361 shares in the last quarter. AQR Capital Management LLC purchased a new position in CytomX Therapeutics during the second quarter valued at $717,000. Two Sigma Investments LP lifted its position in CytomX Therapeutics by 106.9% during the fourth quarter. Two Sigma Investments LP now owns 740,724 shares of the biotechnology company’s stock valued at $1,185,000 after purchasing an additional 382,763 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in CytomX Therapeutics by 55.0% during the first quarter. Dimensional Fund Advisors LP now owns 809,140 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 287,113 shares in the last quarter. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Trading Down 5.4 %

CytomX Therapeutics stock opened at $1.76 on Thursday. The firm has a market cap of $119.20 million, a price-to-earnings ratio of -87.96 and a beta of 1.00. The stock has a fifty day simple moving average of $2.03 and a two-hundred day simple moving average of $1.62. CytomX Therapeutics has a 12 month low of $1.04 and a 12 month high of $2.86.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, March 11th. The biotechnology company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The business had revenue of $26.61 million during the quarter, compared to analyst estimates of $23.36 million. On average, equities research analysts forecast that CytomX Therapeutics will post -0.21 EPS for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.